Worst IPOs of 2009: Biggest Stock Flops
Omeros (OMER) is hoping to win in the marketplace by mixing a cocktail of existing drugs to preemptively curb inflammation during surgery.
But finding commercial success with these PharmacoSurgery products won't be easy. "Rather than developing novel therapies of its own, Omeros simply repackages over-the-counter and prescription generic medications for use in its drug delivery system," Morningstar wrote in a note. "And without a novel product on its hands or a critical unmet need to address, surgeons could be hesitant to replace their current treatment practices with Omeros' pricier offerings."
Omeros began trading on Oct. 8, pricing its 6.82 million shares at $10. But investors, unsure about the company's long-term potential, have since sent shares in Omeros plunging by 30% to close at $7.01 on Dec. 8.In the third quarter, Omeros reported a loss of $3.9 million or $1.34 a share, compared to a loss of $7.4 million or $2.54, in the year-ago quarter.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV